In recent years, China’s innovative drug sector has experienced explosive growth, with numerous domestic companies transitioning from generic to original drug development and producing a wave of globally competitive drug candidates. However, innovative drug R&D is characterized by long timelines, high investment, and significant risk—making it difficult for companies to sustain long-term success based solely on a single product or short-term breakthrough. As a result, extending the value chain has become an industry imperative. This means building capabilities across the entire lifecycle—not just R&D, but also clinical development, regulatory submissions, manufacturing, commercialization, and global expansion. Only by establishing a comprehensive value chain can companies evolve from merely ‘having a drug’ to delivering ‘high-quality drugs’ and ultimately ‘globally impactful medicines.’ Furthermore, strategic collaboration with CROs, CDMOs, and AI-driven drug discovery platforms can significantly enhance efficiency and reduce costs. In the future, innovative pharmaceutical companies equipped with end-to-end lifecycle management capabilities and a global perspective will be best positioned to navigate market cycles and achieve sustainable success.
近年来，中国创新药产业迎来爆发式增长，大量本土企业从仿制药向原研药转型，涌现出一批具有全球竞争力的候选药物。然而，创新药的研发周期长、投入大、风险高，仅靠单一产品或短期突破难以支撑企业的长期发展。因此，延长价值链成为行业共识——即在研发之外，强化临床开发、注册申报、生产制造、商业化运营乃至国际化布局等全链条能力。只有构建完整的价值链体系，企业才能在激烈的市场竞争中实现从‘有药’到‘好药’再到‘全球药’的跃迁。此外，通过与CRO、CDMO、AI制药平台等生态伙伴协同，也能有效提升效率、降低成本。未来，具备全生命周期管理能力和全球化视野的创新药企，将更有可能穿越周期、行稳致远。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/19461.html